{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:04:36Z","timestamp":1784120676195,"version":"3.55.0"},"reference-count":35,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196112"],"award-info":[{"award-number":["1196112"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arthritis Australia & Arthritis and Osteoporosis Western Australia","award":["26-AA\/AWA-F"],"award-info":[{"award-number":["26-AA\/AWA-F"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Whether primary aldosteronism (PA), the most common endocrine cause of hypertension (HTN), contributes to HTN and cardiovascular disease burden in systemic sclerosis (SSc) has never been explored. We aimed to assess the prevalence and management of HTN, prevalence of positive PA screening test results and the associations between markers of PA with HTN and SSc-related outcomes in SSc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from adult SSc patients and normotensive healthy controls (HC) were analysed in this single-centre study. HTN was defined as blood pressures \u2265140\/90\u2009mm Hg on two visits or as documented in medical records. PA screening was performed using the aldosterone:renin ratio (ARR). Associations between biomarkers of PA (renin, aldosterone, ARR, hybrid steroid 18-hydroxycortisol (18OHF)) with HTN and SSc-related outcomes were assessed using multivariable regression modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 112 SSc patients (median (IQR) age 60 (49, 69) years, 79% female) and 48 HC (median (IQR) age 42.5 (31, 57) years, 52% female) were analysed. At baseline, 41 SSc patients (37%) had HTN, increasing to 52% of the cohort at the last follow-up visit (median follow-up 5.1 years). The prevalence of positive baseline ARR in SSc was 8% (9\/112), corresponding to 12% (5\/41) in the hypertensive subset. No associations were observed between biomarkers of PA and SSc-related renal and cardiovascular outcomes or HTN at last follow-up visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HTN was common in this SSc cohort, and prevalence of positive PA screening test was estimated at 12% among hypertensive SSc patients, supporting consideration of PA screening in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-006930","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:10:20Z","timestamp":1784117420000},"page":"e006930","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of markers of primary aldosteronism in systemic sclerosis and their relationships with renal and cardiovascular outcomes"],"prefix":"10.1136","volume":"12","author":[{"given":"Aurore","family":"Collet","sequence":"first","affiliation":[{"name":"INSERM, CHU Lille, Institute for Translational Research in Inflammation (INFINITE), University of Lille, Lille, France"},{"name":"INSERM, Lille, France"},{"name":"Institute of Immunology, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Sanges","sequence":"additional","affiliation":[{"name":"INSERM, CHU Lille, Institute for Translational Research in Inflammation (INFINITE), University of Lille, Lille, France"},{"name":"D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, CHU Lille, Lille, France"},{"name":"NordOuest, M\u00e9diterran\u00e9e et Guadeloupe (CeRAINOM), Centre National de R\u00e9f\u00e9rence Maladies Auto-immunes Syst\u00e9miques Rares du Nord, Lille, France"},{"name":"Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases (ReCONNET), Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Espiard","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodale","family":"Djobo","sequence":"additional","affiliation":[{"name":"Service Hormonologie, M\u00e9tabolisme, Nutrition, Oncologie, P\u00f4le de Biologie Pathologie G\u00e9n\u00e9tique, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4923-6587","authenticated-orcid":false,"given":"Romain","family":"Vankemmel","sequence":"additional","affiliation":[{"name":"Service Hormonologie, M\u00e9tabolisme, Nutrition, Oncologie, P\u00f4le de Biologie Pathologie G\u00e9n\u00e9tique, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dubucquoi","sequence":"additional","affiliation":[{"name":"INSERM, CHU Lille, Institute for Translational Research in Inflammation (INFINITE), University of Lille, Lille, France"},{"name":"INSERM, Lille, France"},{"name":"Institute of Immunology, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7432-847X","authenticated-orcid":false,"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, CHU Lille, Lille, France"},{"name":"NordOuest, M\u00e9diterran\u00e9e et Guadeloupe (CeRAINOM), Centre National de R\u00e9f\u00e9rence Maladies Auto-immunes Syst\u00e9miques Rares du Nord, Lille, France"},{"name":"Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases (ReCONNET), Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Douillard","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[{"name":"INSERM, CHU Lille, Institute for Translational Research in Inflammation (INFINITE), University of Lille, Lille, France"},{"name":"INSERM, Lille, France"},{"name":"D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, CHU Lille, Lille, France"},{"name":"NordOuest, M\u00e9diterran\u00e9e et Guadeloupe (CeRAINOM), Centre National de R\u00e9f\u00e9rence Maladies Auto-immunes Syst\u00e9miques Rares du Nord, Lille, France"},{"name":"Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases (ReCONNET), Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology and Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-0800","authenticated-orcid":false,"given":"Fabien B","family":"Vincent","sequence":"additional","affiliation":[{"name":"Rheumatology Research Group, Centre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026071505101725000_12.3.e006930.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01692-0"},{"key":"2026071505101725000_12.3.e006930.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.06.002"},{"key":"2026071505101725000_12.3.e006930.3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.5114\/ada.2022.120881","article-title":"Arterial hypertension in systemic sclerosis","volume":"39","author":"Wielosz","year":"2022","journal-title":"Postepy Dermatol Alergol"},{"key":"2026071505101725000_12.3.e006930.4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013405","article-title":"Cardiovascular manifestations of systemic sclerosis: a Danish nationwide cohort study","volume":"8","author":"Butt","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026071505101725000_12.3.e006930.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201176"},{"key":"2026071505101725000_12.3.e006930.6","doi-asserted-by":"publisher","DOI":"10.1177\/23971983241313096"},{"key":"2026071505101725000_12.3.e006930.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-57275-9","article-title":"Association between systemic sclerosis and risk of cerebrovascular and cardiovascular disease: a meta-analysis","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"2026071505101725000_12.3.e006930.8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023009","article-title":"Systemic sclerosis and risk of cardiovascular disease: a PRISMA-compliant systematic review and meta-analysis of cohort studies","volume":"99","author":"Cen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2026071505101725000_12.3.e006930.9","first-page":"2312","article-title":"Primary aldosteronism: an unsuspected culprit of hypertension in systemic lupus erythematosus?","volume":"41","author":"Feng","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2026071505101725000_12.3.e006930.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.01.447"},{"key":"2026071505101725000_12.3.e006930.11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/HJH.0000000000002300","article-title":"Risk of new-onset autoimmune diseases in primary aldosteronism: a nation-wide population-based study","volume":"38","author":"Er","year":"2020","journal-title":"J Hypertens"},{"key":"2026071505101725000_12.3.e006930.12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/rheumatology\/kead699","article-title":"Steroid hormones in systemic sclerosis: associations with disease characteristics and modifications during scleroderma renal crisis","volume":"64","author":"Collet","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026071505101725000_12.3.e006930.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424"},{"key":"2026071505101725000_12.3.e006930.14","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000231"},{"key":"2026071505101725000_12.3.e006930.15","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2026071505101725000_12.3.e006930.16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"2026071505101725000_12.3.e006930.17","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.40809","article-title":"Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology","volume":"71","author":"Butler","year":"2019","journal-title":"Arthritis & Rheumatology"},{"key":"2026071505101725000_12.3.e006930.18","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065"},{"key":"2026071505101725000_12.3.e006930.19","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an Endocrine Society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071505101725000_12.3.e006930.20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12020-023-03520-6","article-title":"Screening for primary aldosteronism on and off interfering medications","volume":"83","author":"Li","year":"2024","journal-title":"Endocrine"},{"key":"2026071505101725000_12.3.e006930.21","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001524","article-title":"Evaluation of primary aldosteronism testing in hypertensive patients with SLE in a tertiary hospital","volume":"12","author":"Wong","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026071505101725000_12.3.e006930.22","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/acr.23880","article-title":"Increased incidence of resistant hypertension in patients with systemic lupus erythematosus: a retrospective cohort study","volume":"72","author":"Gandelman","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026071505101725000_12.3.e006930.23","doi-asserted-by":"crossref","DOI":"10.7326\/L20-1097","article-title":"The unrecognized prevalence of primary aldosteronism","volume":"173","author":"Vaidya","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026071505101725000_12.3.e006930.24","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283656b54"},{"key":"2026071505101725000_12.3.e006930.25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071505101725000_12.3.e006930.26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.31128\/AJGP-07-19-4995","article-title":"Screening for primary aldosteronism: how to adjust existing antihypertensive medications to avoid diagnostic errors","volume":"49","author":"Gurgenci","year":"2020","journal-title":"Aust J Gen Pract"},{"key":"2026071505101725000_12.3.e006930.27","doi-asserted-by":"crossref","DOI":"10.1111\/jch.70218","article-title":"Optimal cut-off values of the aldosterone-renin ratio in different age groups for primary aldosteronism screening","volume":"28","author":"Li","year":"2026","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026071505101725000_12.3.e006930.28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cen.14199","article-title":"Age- and sex-specific reference ranges are needed for the aldosterone\/renin ratio","volume":"93","author":"Solanki","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026071505101725000_12.3.e006930.29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae178"},{"key":"2026071505101725000_12.3.e006930.30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","article-title":"Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071505101725000_12.3.e006930.31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071505101725000_12.3.e006930.32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/cen.70106","article-title":"Improvement of health-related quality of life and mental health after unilateral adrenalectomy for primary aldosteronism","volume":"105","author":"Fuld","year":"2026","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026071505101725000_12.3.e006930.33","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1161\/HYPERTENSIONAHA.123.21474","article-title":"Primary aldosteronism in chronic kidney disease: blood pressure control and kidney and cardiovascular outcomes after surgical versus medical management","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"2026071505101725000_12.3.e006930.34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S2213-8587(25)00263-3","article-title":"Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis","volume":"13","author":"Katsuragawa","year":"2025","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2026071505101725000_12.3.e006930.35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:10:24Z","timestamp":1784117424000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-006930"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006930","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}